The Ambu®AuraGain™ laryngeal mask (LM) (Ambu A/S, Ballerup, Denmark) is one of the few readily available secondgeneration supraglottic airway devices (SADs) that offer a conduit for fibreoptic-guided endotracheal intubation. We aimed to compare fibreoptic intubation through this device with the LMA® (laryngeal mask airway) Fastrach™ (Teleflex Medical, Co. Westmeath, Ireland), which has been a recommended dedicated rescue device for the management of the unanticipated difficult airway. This randomised controlled trial compared a previously described fibreoptic score in 116 patients with no known airway pathology, who had asleep fibreoptic endotracheal intubation via either the AuraGain LM or the LMA Fastrach. Time, ease and success rate of SAD and endotracheal tube (ETT) insertion and complications were recorded. The AuraGain LM demonstrated better laryngeal alignment with 29 out of 59 patients in the AuraGain LM (AG) group having a Grade 4 view (only vocal cords visible), compared to 20 out of 54 patients in the LMA Fastrach (FT) group (P=0.003). It allowed significantly quicker and easier ETT intubation when used as a conduit. The AuraGain LM was also quicker to insert compared to the Fastrach LMA. Similar rates of minor complications, such as sore throat and dysphonia occurred in both groups. Our study indicates that when used in patients with complete muscle relaxation and no known airway pathology, the AuraGain LM achieves better laryngeal alignment and quicker, easier and more successful fibreoptic-guided ETT intubation than the Fastrach LMA.
The Difficult Airway Society (DAS) guideline for the management of the unanticipated difficult airway states that if the initial intubation attempt using laryngoscopy fails, a supraglottic airway device (SAD) should be placed to achieve oxygenation and subsequent intubation via the device 1 . The LMA® (laryngeal mask airway) Fastrach™ (Teleflex Medical, Co. Westmeath, Ireland) has been the recommended device for many years because its design facilitates intubation with or without the aid of a fibreoptic bronchoscope 2 . In 2015, the DAS revised the guideline and recommended the use of a second-generation SAD rather than the long-established Fastrach LMA in the management of an unanticipated difficult airway 1 . It also recommended the use of fibreoptic-guided intubation through the SAD rather than blind attempts. There are currently many new secondgeneration SADs available in the market. However, many of them, such as the LMA® Supreme™ and the ProSeal TM LMA® (Teleflex Medical, Co. Westmeath, Ireland), are not designed to be an endotracheal tube (ETT) conduit owing to a relatively narrow lumen. In the revised DAS guideline no particular SAD is recommended. Appropriate choice of a second-generation SAD is important, especially if one plans to use it as a conduit for subsequent intubation during a difficult airway situation.
In this study, we explored the use of fibreoptic intubation through the Ambu® AuraGain™ laryngeal mask (Ambu A/S, Ballerup, Denmark) in adult patients. We investigated whether it could be a clinically useful alternative to the Fastrach LMA. The Ambu AuraGain LMs are commonly used in patients who are having general anaesthesia under spontaneous ventilation and hence are readily available. Unlike the LMA Supreme, the AuraGain possesses a shortand wide-bore preformed airway tube with no mask aperture bar [3] [4] [5] . This allows passage of wide internal diameter ETTs. It is currently one of the few second-generation SADs that can also act as a conduit for endotracheal intubation. When faced with a failed intubation scenario, if the AuraGain LMA is readily available and the anaesthetist is familiar with its use, it could potentially be a useful tool in this situation.
In this randomised controlled study, we compared fibreoptic intubation through the Ambu AuraGain LM and the conventional LMA Fastrach, using a standardised fibreoptic score described by Brimacombe and Berry 6 , in adult patients without known airway pathology requiring orotracheal intubation during general anaesthesia.
Materials and methods
After obtaining approval from the Melbourne Health Human Research Ethics Committee (MH Project Number: 2015.104) and registration from the Australian New Zealand Clinical Trials Registry (Registry No.: ACTRN12615000300572), we recruited 116 patients scheduled for surgery requiring orotracheal intubation under general anaesthesia at the Royal Melbourne Hospital for this study (Figure 1 ). We recruited patients if they were ≥18 years of age and of American Society of Anesthesiologists (ASA) physical status 1-3. Exclusion criteria included patients who were non-English speaking, who were predicted to have a difficult airway, or who had any contraindication to the use of an SAD. These included an airway requiring fibreoptic intubation, any known laryngeal pathology, weight >100 kg, inter-incisor distance <2.5 cm, or aspiration risk. After written informed consent was obtained, patients were assigned, using a computer-generated randomisation method, to having their airway intubated fibreoptically through either an AuraGain LM or Fastrach LMA. Allocations were concealed in opaque numbered and sealed envelopes prior to recruitment. The allocation was revealed only after the patient consented to participate in the study. Patients were blinded as to their allocation group.
The intubation was performed by an experienced anaesthetist, defined as having more than 10 years of clinical experience since the commencement of specialist training as well as familiarity with both LM devices. All anaesthetists involved in intubation for this study participated in a standardised educational program consisting of an interactive tutorial and practice on an airway manikin. Anaesthetists had completed >10 uses on each device prior to the study.
The size of the LM was chosen by the intubating anaesthetist based on the patient's weight and airway assessment. For each participant the following data were recorded preoperatively: age, sex, height, weight, ASA physical status, airway characteristics (Mallampati score and thyromental distance), and type of surgery.
Patients were anaesthetised in an area with appropriate monitoring, resuscitation equipment and assistance in accordance with the Australian and New Zealand College of Anaesthetists guidelines. After pre-oxygenation with 100% oxygen to reach an end-tidal O 2 ≥70%, patients were given induction agents at the discretion of the anaesthetist involved with the patient's overall care. Patients were placed in the sniffing position with the head on a pillow and ventilated via a facemask with 100% oxygen.
After complete muscle paralysis (train of four = 0), the allocated SAD was inserted by the study anaesthetist as per the manufacturer's instructions. The cuff was filled with air to the maximum manufacturer's recommended volume (size 3, 20 ml; size 4, 30 ml; size 5, 40 ml). An effective supraglottic airway was defined by resistance to further downward motion, chest wall movement, presence of an end-tidal CO 2 waveform, and movement of the reservoir bag during ventilation. Where more than one insertion attempt was required, the patient received bag-and-mask ventilation between attempts. A failed insertion attempt was defined as complete withdrawal of the device from the mouth following an unsuccessful placement. After two attempts the device was deemed to have failed and the study protocol was abandoned-the treating anaesthetist then proceeded with the airway management of their choosing according to the needs of the patient and the surgery.
After achieving satisfactory ventilation via the allocated SAD, fibreoptic-guided tracheal intubation then commenced.
A fibreoptic scope loaded with a pre-lubricated, dedicated ETT (Mallinckrodt [Medtronic, Minneapolis, MN, USA] oral ETT, size 6.5 for LM size 3, 7.0 for LM size 4 and 8.0 for LM size 5) was inserted through the airway. Once the scope tip reached the glottic opening, the fibreoptic scoring of the glottis view was assessed by the study anaesthetist using a standardised Brimacombe and Berry scoring system, which is opposite to the direct laryngoscopy views grading (1-vocal cords not visible, 2-vocal cords plus anterior epiglottis visible, 3-vocal cords plus posterior epiglottis visible, and 4-only vocal cords visible) 6 . The scope was inserted into the trachea, the ETT railroaded into the trachea, and the fibrescope was then removed. Proper placement of the ETT was confirmed clinically and by the presence of the endtidal CO 2 trace. The SAD was then removed according to the manufacturer's instructions. The rationale for removing the SAD as part of the study protocol was because we wished to find out how easy or difficult it was to remove the SAD, as it would be sometimes necessary to do so due to surgical access or patient position. After this manoeuvre the position of the ETT relative to the carina was assessed bronchoscopically.
A maximum of two attempts was allowed with fibreopticguided intubation. An alternative airway management plan could be instituted at the discretion of the anaesthetist if a failed intubation was encountered after two attempts with the allocated device.
The primary outcome was fibreoptic scores which evaluated the laryngeal alignment according to the standardised scale proposed by Brimacombe and Berry 6 . Secondary outcomes included time taken to insert the SAD, time taken for endotracheal intubation, number of insertion attempts for the allocated SAD, number of fibreoptic-guided intubation attempts, proportion of successful and failed SAD insertions and endotracheal intubations, ease of intubation, and any associated complications. All of the data were collected by an independent observer on a standardised case report form.
Time for insertion of the SAD was taken from the moment of removal of the facemask until the first appearance of the end-tidal CO 2 capnography trace after device insertion. ETT insertion time before removal of the SAD was taken from disconnection of the SAD from the circuit until the reappearance of the capnography trace upon attachment to the ETT. This was a subset of overall ETT insertion time (which included SAD removal), which was taken from disconnection of the SAD from the circuit prior to ETT insertion, to reappearance of the capnography trace when the ETT was reconnected to the circuit after the SAD was removed. Ease of insertion was surveyed as a visual analogue scale from 0 to 100 mm. Any complications such as injury to lips, oral mucosa or dentition, hypoxia (SpO 2 <90%) during intubation, sore throat, dysphagia, or dysphonia, were recorded.
Based on a previous study 7 , the LMA Fastrach achieved 50% good alignment using the Brimacombe and Berry fibreoptic scoring system 6 . To demonstrate a clinically important improvement of 25%, 55 patients were required in each group to achieve 80% power at the 0.05 level of significance. Therefore we recruited 120 patients in total to account for dropouts. The chi-squared test was used to examine the standardised fibreoptic scores, the number of SAD insertion attempts, the number of intubation attempts, the proportion of successful SAD insertions and intubations, and the number of complications. The Mann-Whitney U test was used to examine the time taken for successful SAD insertion, time taken for successful intubation, and the ease of intubation. A P-value <0.05 was considered statistically significant. Statistical analysis was performed using Stata 13.0 (Statacorp, College Station, TX, USA).
Results
The baseline characteristics of the patients were similar in both groups ( Table 1 ). The glottic visualisation was superior in the AuraGain LM (AG) group compared with the LMA Fastrach (FT) group, as shown in Table 2 . There was a significantly higher proportion of patients with a Brimacombe and Berry score of grade four and significantly fewer with grade one in the AG group compared to the FT group.
The SAD insertion times, and the ETT insertion times before removal of the SAD and overall were significantly shorter in the AG group compared to the FT group (Table 3 ). The success rate of both SAD and ETT insertion was 100% in the AG group. There were three failed SAD insertions and nine failed ETT insertions (P=0.001) with the Fastrach LMA. Using the visual analogue scale of 0 to 10, the ETT insertion was performed with significantly greater ease in the AG group than in the FT group (Table 3) .
There was no statistically significant difference in the complication rate between the two groups ( Table 4 ). The most common complication reported postoperatively was dysphonia, particularly in the FT group (although not statistically significant). A similar proportion of patients reported having a sore throat postoperatively in both groups. One patient sustained an oral injury in the FT group. All of the complications were mild and did not require further management.
Discussion
In this study, the AuraGain LM was found to be superior to the Fastrach LMA by providing a better laryngeal alignment and quicker insertion time. It also allowed quicker and easier ETT intubation when used as a conduit.
The finding of the primary outcome that the AuraGain LM provides an improved Brimacombe and Berry score is consistent with previous studies in both adult 3,7 and paediatric 7, 8 patients when compared with other secondgeneration SADs. A better laryngeal alignment may have explained a quicker and easier ETT intubation in the AG group compared to the FT group. However, only 49% of the patients in the AG group and 37% in the FT group achieved the optimal fibreoptic view for ETT insertion (grade 4 Brimacombe and Berry score). This supports the current DAS 2015 Guideline 1 that blind intubation through an SAD is not recommended.
Although the body mass index was similar between the two groups, there were fewer size 5 LMAs and more size 3 LMAs used in the AG group compared to the FT group. This might be because more patients with a shorter thyromental distance were present in the AG group than the FT group (Table 1) . Moreover, the LM cuff of the AuraGain is relatively prominent. A previous study examining the use of the Ambu AuraGain for laparoscopic gynaecological surgery found that the AuraGain LM achieved a tighter and more consistent perilaryngeal seal than the Supreme LMA 7 . It was suggested that the design feature of a wider airway tube conferred a more prominent posterior aspect to the LM cuff resulting in this improved seal 3, 7, 9 . Despite a bulkier LM cuff, the rating of ease of SAD insertion was similar between the two groups. The rigid handle of the Fastrach might have hindered the ease of insertion and potentially prolonged the insertion time of the device.
The prospective observational study by Kriege et al 9 comparing the use of the AuraGain with the Supreme LMA reported a higher incidence of airway complications in the AG group (25% in the AuraGain versus 14% in the Supreme LMA group) consisting of post-removal complications such as blood staining on the cuff, coughing and sore throat.
While not statistically significant, the most common complication in the AG group was sore throat, followed by dysphonia. Our rates were comparable to those found in a previous study 9 . The FT group also displayed similar rates of complications, with slightly lower rates of sore throat but higher rates of dysphonia. Neither LM was found to cause serious complications during intubation, although we acknowledge that this study was performed in a controlled, non-emergency situation with adequate pre-oxygenation.
There were several limitations of this study. Firstly, it was not possible to blind the treatment allocations from the anaesthetist performing the intubation, nor the independent observer recording the data. It was possible that this could have led to bias if an anaesthetist had a preference for one particular LM. However, the protocol had clearly defined start-and endpoints of device insertion with regard to timing, and a standardised fibreoptic grading score. Secondly, the study was not powered to compare complications between the two groups. Hence, these results should be interpreted with caution.
Another limitation of this study was that only anaesthetists experienced in the use of both devices participated in the study. This might have contributed to higher rates of successful insertion of the SAD and ETT than would have occurred with a novice user. We know from previous studies that performance success using airway devices improves with prior training 10 , emphasising the importance of familiarity with these devices before requiring them in an emergency situation. One advantage noted of the AuraGain LMA when compared to the Fastrach LMA is its relatively lower cost, and therefore it has been readily available and commonly used as a routine airway device for patients having general anaesthesia with spontaneous ventilation. This improves anaesthetists' familiarity with the device and potentially enhances the skill required for successful use of the device in an emergency situation.
Finally, we note that this study did not include patients with known laryngeal pathology or a predicted difficult airway. Generalisability of our study findings is therefore possibly limited in these patient groups. The clinical findings of this study are nonetheless relevant, because the Ambu AuraGain LM is currently one of the few second-generation SADs that can also act as a conduit for endotracheal intubation. When faced with a failed intubation scenario, a second-generation SAD, rather than the Fastrach LMA, is recommended to be the device of choice as per the revised DAS guideline 1 . If the AuraGain LMA is readily available and the anaesthetist is familiar with its use it could be a useful tool in this situation. In particular, all of the patients in this study received neuromuscular blockade before SAD and ETT insertion. This is consistent with the recommendations of the DAS guideline 1 .
In conclusion, this study showed that when used in patients with complete muscle relaxation and no known airway pathology, the AuraGain LM achieved better laryngeal alignment and quicker, easier and more frequently successful fibreoptic-guided ETT intubation when compared to the Fastrach LMA. Further studies will be required to show whether these findings are also applicable to patients with a known difficult airway.
